Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with RET-altered solid tumors in the US

References

• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi: 10.1016/j.jval.2013.08.2291.
   PubMed Web of Science ®Google Scholar
• Schlander M, Dintsios CM, Gandjour A. Budgetary impact and cost drivers of drugs for rare and ultrarare diseases. Value Health. 2018;21(5):525–531. doi: 10.1016/j.jval.2017.10.015.
   PubMed Web of Science ®Google Scholar
• Hay JW. Now is the time for transparency in value-based healthcare decision modeling. Value Health. 2019;22(5):564–569. doi: 10.1016/j.jval.2019.01.009.
   PubMed Web of Science ®Google Scholar
• Schiller J, Eckhardt H, Schmitter S, et al. Challenges and solutions for the benefit assessment of tumor-agnostic therapies in Germany. Value Health. 2023;26(6):854–864. doi: 10.1016/j.jval.2023.01.011.
   PubMed Web of Science ®Google Scholar
• Weis LN, Tolaney SM, Barrios CH, et al. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? NPJ Breast Cancer. 2021;7(1):120. doi: 10.1038/s41523-021-00328-3.
   PubMed Web of Science ®Google Scholar
• Hobbs BP, Pestana RC, Zabor EC, et al. Basket trials: review of current practice and innovations for future trials. J Clin Oncol. 2022;40(30):3520–3528. doi: 10.1200/JCO.21.02285.
   PubMed Web of Science ®Google Scholar
• Raez LE, Santos ES. Tumor type-agnostic treatment and the future of cancer therapy. Target Oncol. 2018;13(5):541–544. doi: 10.1007/s11523-018-0593-y.
   PubMed Web of Science ®Google Scholar
• Sullivan S, Carlson J, Hansen R, et al. Challenges estimating the economic value of tissue-agnostic anti-cancer treatments. J Manag Care Spec Pharm. 2018;24:10A–32.
   Google Scholar
• Mulligan LM. 65 YEARS OF THE DOUBLE HELIX: exploiting insights on the RET receptor for personalized cancer medicine. Endocr Relat Cancer. 2018;25(8):T189–T200. doi: 10.1530/ERC-18-0141.
   PubMed Web of Science ®Google Scholar
• Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res. 2017;23(8):1988–1997. doi: 10.1158/1078-0432.CCR-16-1679.
   PubMed Web of Science ®Google Scholar
• Davis JL, Vargas SO, Rudzinski ER, et al. Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. Histopathology. 2020;76(7):1032–1041. doi: 10.1111/his.14082.
   PubMed Web of Science ®Google Scholar
• Santoro M, Moccia M, Federico G, et al. RET gene fusions in malignancies of the thyroid and other tissues. Genes (Basel). 2020;11(4):424. doi: 10.3390/genes11040424.
   PubMed Web of Science ®Google Scholar
• Regua AT, Najjar M, Lo HW. RET signaling pathway and RET inhibitors in human cancer. Front Oncol. 2022;12:932353. doi: 10.3389/fonc.2022.932353.
   PubMedGoogle Scholar
• Li AY, McCusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019;81:101911. doi: 10.1016/j.ctrv.2019.101911.
   PubMed Web of Science ®Google Scholar
• Addeo A, Miranda-Morales E, den Hollander P, et al. RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives. Pharmacol Ther. 2023;242:108344. doi: 10.1016/j.pharmthera.2023.108344.
   PubMed Web of Science ®Google Scholar
• Zhou L, Li J, Zhang X, et al. An integrative pan cancer analysis of RET aberrations and their potential clinical implications. Sci Rep. 2022;12(1):13913. doi: 10.1038/s41598-022-17791-y.
   PubMed Web of Science ®Google Scholar
• Parimi V, Tolba K, Danziger N, et al. Genomic landscape of 891 RET fusions detected across diverse solid tumor types. NPJ Precis Oncol. 2023;7(1):10. doi: 10.1038/s41698-023-00347-2.
   PubMed Web of Science ®Google Scholar
• Andreev-Drakhlin A, Roszik J, Subbiah V. The landscape of RET alterations from 56,970 adult patients with cancer: clinical implications. J Clin Oncol. 2019;37(15_suppl):3106. doi: 10.1200/JCO.2019.37.15_suppl.3106.
   Web of Science ®Google Scholar
• FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. 2020 [cited 2023 Jun 9]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions
   Google Scholar
• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383(9):813–824. doi: 10.1056/NEJMoa2005653.
   PubMed Web of Science ®Google Scholar
• FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. 2022 [cited 2023 Jun 8]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors
   Google Scholar
• Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022;23(10):1261–1273. doi: 10.1016/S1470-2045(22)00541-1.
   PubMed Web of Science ®Google Scholar
• Hess LM, Han Y, Zhu YE, et al. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer. 2021;21(1):28. doi: 10.1186/s12885-020-07714-3.
   PubMedGoogle Scholar
• Parikh R, Hess LM, Esterberg E, et al. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer. Thyroid Res. 2022;15(1):2. doi: 10.1186/s13044-021-00119-9.
   PubMed Web of Science ®Google Scholar
• Nabhan F, Dedhia PH, Ringel MD. Thyroid cancer, recent advances in diagnosis and therapy. Int J Cancer. 2021;149(5):984–992. doi: 10.1002/ijc.33690.
   PubMed Web of Science ®Google Scholar
• Bhandari NR, Cinfio F, Souri S, et al. Estimation of the population of patients with ret-altered tumors in the United States. Value Health. 2020;3(5);Supple 1. Available from: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/99990
   Google Scholar
• Selpercatinib Prescribing Information. 2022 [cited 2023 Jul 24]. Available from: https://pi.lilly.com/us/retevmo-uspi.pdf
   Google Scholar
• GAVRETO Prescribing Information. 2020 [cited 2023 Aug 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf
   Google Scholar
• IPSOS Oncology Monitor (US). 2021. [cited 2023 Aug 17]. Available from: https://www.ipsos.com/
   Google Scholar
• Kim J, Bradford D, Larkins E, et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res. 2021;27(20):5452–5456. doi: 10.1158/1078-0432.CCR-21-0967.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Thyroid Carcinoma. Version 4. 2023. [cited 2023 Sep 15]. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
   Google Scholar
• U.S. Department of Labor. Bureau of Labor Statistics. Consumer Price Index-all urban consumers, U.S, medical care, 2022 half year value; 2022 [cited 2023 Jun 8]. Available from: http://data.bls.gov/cgi-bin/surveymost?cu
   Google Scholar
• [RED BOOK] Micromedex® 2.0. (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA; 2022 [cited 2023 Jul 7]. Available from: http://www.micromedexsolutions.com/
   Google Scholar
• CMS ASP File. 2022 [cited 2023 Jun 8]. Available from: https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files
   Google Scholar
• Avalere Health LLC. Chart 4.5: aggregate hospital payment-to-cost ratios for private payers, Medicare and Medicaid. Trendwatch Chartbook 2021. American Hospital Association; 2021 [cited 2023 Jul 9]. Available from: https://www.aha.org/system/files/media/file/2020/10/TrendwatchChartbook-2020-Appendix.pdf
   Google Scholar
• [HCUP 2022] HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, MD; [cited 2023 Jun 8]. Available from: https://hcupnet.ahrq.gov/. For more information about HCUP data see http://www.hcup-us.ahrq.gov/
   Google Scholar
• Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. J Clin Oncol Precis Oncol. 2018;2:1–13. doi: 10.1200/PO.18.00169.
   PubMed Web of Science ®Google Scholar
• Malangone-Monaco E, Doleh Y, Cole A, et al. The economic burden of metastatic pancreatic cancer. Pancreatology. 2020;20(7):1434–1441. doi: 10.1016/j.pan.2020.09.002.
   PubMed Web of Science ®Google Scholar
• Phase 1/2 Study of the Highly-selective RET Inhibitor. Pralsetinib (BLU-667), in participants with thyroid cancer, non-small cell lung cancer, and other advanced solid tumors (ARROW). [cited 2023 Oct 26]. Available from: https://clinicaltrials.gov/study/NCT03037385
   Google Scholar
• Drusbosky LM, Rodriguez E, Dawar R, et al. Therapeutic strategies in RET gene rearranged non-small cell lung cancer. J Hematol Oncol. 2021;14(1):50. doi: 10.1186/s13045-021-01063-9.
   PubMed Web of Science ®Google Scholar
• Puliafito I, Esposito F, Prestifilippo A, et al. Target therapy in thyroid cancer: current challenge in clinical use of tyrosine kinase inhibitors and management of side effects. Front Endocrinol. 2022;13:860671. doi: 10.3389/fendo.2022.860671.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER Cancer Stat Facts: thyroid cancer. [cited 2023 Jun 9]. Available from: https://seer.cancer.gov/statfacts/html/thyro.html
   Google Scholar
• Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825–835. doi: 10.1056/NEJMoa2005651.
   PubMed Web of Science ®Google Scholar
• Duff S, Bargiacchi F, Norregaard C, et al. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations. J Manag Care Spec Pharm. 2022;28(2):218–231. doi: 10.18553/jmcp.2021.21308.
   PubMed Web of Science ®Google Scholar
• Murray S, Subbiah V, Sherman SI, et al. Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study. Thyroid Res. 2023;16(1):22. doi: 10.1186/s13044-023-00166-4.
   PubMed Web of Science ®Google Scholar
• Cascetta P, Sforza V, Manzo A, et al. RET inhibitors in non-small-cell lung cancer. Cancers (Basel). 2021;13(17):4415. doi: 10.3390/cancers13174415.
   PubMed Web of Science ®Google Scholar
• Elisei R, Grande E, Kreissl MC, et al. Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe. Front Oncol. 2023;13:1141314. doi: 10.3389/fonc.2023.1141314.
   PubMedGoogle Scholar
• Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869–1876. doi: 10.1093/annonc/mdy137.
   PubMed Web of Science ®Google Scholar
• Drilon A, Hu ZI, Lai GGY, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151–167. doi: 10.1038/nrclinonc.2017.175.
   PubMed Web of Science ®Google Scholar
• Zhou C, Solomon B, Loong HH, et al. First-Line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023;389(20):1839–1850. doi: 10.1056/NEJMoa2309457.
   PubMed Web of Science ®Google Scholar
• Hadoux J, Elisei R, Brose MS, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023;389(20):1851–1861. doi: 10.1056/NEJMoa2309719.
   PubMed Web of Science ®Google Scholar
• Gristina V, Pisapia P, Barraco N, et al. The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? Expert Rev Mol Diagn. 2023;23(10):851–861. doi: 10.1080/14737159.2023.2245752.
   Google Scholar
• Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572. doi: 10.1186/s13063-019-3664-1.
   PubMed Web of Science ®Google Scholar
• Genentech withdraws US indication for pralsetinib in advanced or metastatic RET + medullary thyroid cancer. [cited 2023 Sep 15]. Available from: https://www.onclive.com/view/genentech-withdraws-us-indication-for-pralsetinib-in-advanced-or-metastatic-ret-medullary-thyroid-cancer
   Google Scholar